

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM728301

<b>SUBMISSION TYPE:</b>	RESUBMISSION		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>RESUBMIT DOCUMENT ID:</b>	900685716		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Dr. Reddy's Laboratories Ltd.		09/09/2021	Limited Company: INDIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	BioDelivery Sciences International, Inc.		
<b>Street Address:</b>	Suite #225		
<b>Internal Address:</b>	4131 ParkLake Avenue		
<b>City:</b>	Raleigh		
<b>State/Country:</b>	NORTH CAROLINA		
<b>Postal Code:</b>	27612		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88294114	ELYXYB	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2123553333		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2128138800		
<b>Email:</b>	NY-TM-Admin@goodwinprocter.com		
<b>Correspondent Name:</b>	GOODWIN PROCTER LLP/Janis Nici		
<b>Address Line 1:</b>	620 Eighth Avenue		
<b>Address Line 4:</b>	New York, NEW YORK 10018		
<b>ATTORNEY DOCKET NUMBER:</b>	139006330165		
<b>NAME OF SUBMITTER:</b>	Janis Nici		
<b>SIGNATURE:</b>	/janis nici/		
<b>DATE SIGNED:</b>	05/17/2022		
<b>Total Attachments: 5</b>			
source=BDSI orig cover sheet and assignment doc#page1.tif			
source=BDSI orig cover sheet and assignment doc#page2.tif			
source=BDSI orig cover sheet and assignment doc#page3.tif			

source=BDSI orig cover sheet and assignment doc#page4.tif

source=BDSI orig cover sheet and assignment doc#page5.tif

## ASSIGNMENT OF TRADEMARKS

This ASSIGNMENT OF TRADEMARKS (this "Assignment Agreement") is made this 9th day of September, 2021 (the "Effective Date"), by and between Dr. Reddy's Laboratories Ltd., an Indian corporation ("Assignor"), and BioDelivery Sciences International, Inc., a Delaware corporation ("Assignee"). Unless otherwise specifically provided herein, all capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Asset Purchase Agreement.

WHEREAS, pursuant to that certain Asset Purchase Agreement dated as of August 3, 2021 (as may be amended from time to time, the "Asset Purchase Agreement") by and between Assignor and Assignee, Assignor has agreed to assign to Assignee the trademarks described herein together with such other assets as described in the Asset Purchase Agreement; and

WHEREAS, Assignor has adopted and is using the trademarks described in Exhibit A, attached hereto and made a part hereof (the "Product Trademarks"); and

WHEREAS, pursuant to the Asset Purchase Agreement, Assignee desires to purchase from Assignor, and Assignor has agreed to sell to Assignee, as of the Effective Date all right, title and interest in and to the Product Trademarks as part of the transfer of all or substantially all of the assets of a going business solely related thereto in the United States and Canada as set forth in the Asset Purchase Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Conveyance and Acceptance of Product Trademarks. Upon the terms and subject to the conditions of the Asset Purchase Agreement, effective as of the date of the Closing, Assignor hereby, irrevocably, without reservation, sells, transfers, grants, assigns and conveys (and shall cause to be sold, transferred, granted, assigned and conveyed) to Assignee, free and clear of all Encumbrances other than the Permitted Encumbrances, and Assignee hereby purchases, acquires and accepts from Assignor, all of Assignor's right, title and interest in and to the Product Trademarks (including any common law rights that may exist and are associated therewith) in the United States and Canada, together with the goodwill of the business associated with the Product Trademarks in the United States and Canada, and any and all of Assignor's other rights, privileges, and priorities provided under applicable law with respect to the Product Trademarks in the United States and Canada.

2. Due Authorization. Assignor hereby authorizes and requests the Commissioner for Patents and Product Trademarks of the United States and any other official of any applicable governmental authority to record Assignee as the assignee and owner of the Product Trademarks, and to issue any and all registrations from any and all applications for registration included in the Product Trademarks in and to the name of Assignee.

3. Further Assurances. At Assignee's sole cost and expense, the Assignor shall execute and deliver such additional documents, instruments, conveyances and assurances, prepared by Assignee, and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Assignment Agreement, including the recordation of this Agreement and perfection of Assignee's interest in and to the Product Trademarks in the Territory.

4. Purchase Agreement Controls. Nothing in this Assignment Agreement shall be deemed to supersede, diminish, enlarge or modify any of the provisions of the Asset Purchase Agreement, all of which survive the execution and delivery of this Assignment Agreement as provided and subject to the limitations set forth in the Asset Purchase Agreement. In the event of any conflict or inconsistency between any of the

terms of the Asset Purchase Agreement and any of the terms hereof, the applicable terms of the Asset Purchase Agreement shall govern and control.

5. Assignment; Governing Law; Jurisdiction. This Assignment Agreement and the provisions herein contained shall be binding upon and inure to the benefit of Assignor, Assignee and their respective successors and assigns. The provisions of Section 11.08 (*Governing Law; Jurisdiction*) of the Asset Purchase Agreement shall apply to this Assignment Agreement.


6. Counterparts. This Assignment Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A signed copy of this Assignment Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment Agreement.

*[Remainder of this page intentionally left blank. Signatures on following page.]*

*[Signature Page to Assignment of Trademarks]*

IN WITNESS WHEREOF, the parties, through their duly authorized representatives have executed this Assignment Agreement on the date first set above.


DR. REDDY'S LABORATORIES LTD.

DocuSigned by:  
By:  Erez Israeli

Name: Erez Israeli

Title: Chief Executive Officer

BIODELIVERY SCIENCES INTERNATIONAL, INC.

DocuSigned by:  
By:  Jeffrey A. Bailey

Name: Jeffrey A. Bailey


Title: Chief Executive Officer

*{Signature Page to Assignment of Trademarks}*

**TRADEMARK**  
**REEL: 007714 FRAME: 0316**

EXHIBIT A

Product Trademarks

Mark	Country	Serial Number	Filing Date	Status
ELYXYB	USA	88294114	02/08/2019	Live and allowed on 01/28/2020
 The logo for Elyxyb (celecoxib) Oral Solution, featuring the brand name 'Elyxyb' in a stylized font with a registered trademark symbol, followed by '(celecoxib)' and 'Oral Solution' in a smaller font.	USA	Not Available	Not Available	Not Available